Pfizer Inc. (TSX:PFE)
Canada · Delayed Price · Currency is CAD 12.09
+0.45 (3.87%)
At close: Feb 4, 2026
Pfizer Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 62,579 | 63,627 | 59,554 | 101,175 | 81,288 |
Other Revenue | - | - | -1 | - | - |
| 62,579 | 63,627 | 59,553 | 101,175 | 81,288 | |
Revenue Growth (YoY) | -1.65% | 6.84% | -41.14% | 24.46% | 95.17% |
Cost of Revenue | 15,140 | 16,420 | 17,789 | 34,097 | 30,686 |
Gross Profit | 47,439 | 47,207 | 41,764 | 67,078 | 50,602 |
Selling, General & Admin | 12,964 | 14,771 | 13,836 | 12,200 | 9,562 |
Research & Development | 10,437 | 10,822 | 10,679 | 11,428 | 10,360 |
Amortization of Goodwill & Intangibles | 4,874 | 5,286 | 4,733 | 3,609 | 3,700 |
Other Operating Expenses | 1 | - | - | - | - |
Operating Expenses | 28,276 | 30,879 | 29,248 | 27,237 | 23,622 |
Operating Income | 19,163 | 16,328 | 12,516 | 39,841 | 26,980 |
Interest Expense | -2,671 | -3,091 | -2,209 | -1,238 | -1,291 |
Interest & Investment Income | 868 | 817 | 2,100 | 565 | 202 |
Earnings From Equity Investments | - | 102 | 505 | 436 | 471 |
Currency Exchange Gain (Loss) | - | 50 | 164 | - | - |
Other Non Operating Income (Expenses) | 335 | 652 | 218 | 621 | 1,904 |
EBT Excluding Unusual Items | 17,695 | 14,858 | 13,294 | 40,225 | 28,266 |
Merger & Restructuring Charges | -2,507 | -4,039 | -3,999 | -2,225 | -1,452 |
Gain (Loss) on Sale of Investments | -67 | 1,833 | 1,590 | -1,273 | 1,344 |
Gain (Loss) on Sale of Assets | - | -420 | 222 | - | - |
Asset Writedown | -4,940 | -3,295 | -3,024 | -421 | -86 |
Legal Settlements | -1,057 | -567 | -474 | -230 | -182 |
Other Unusual Items | 10 | -239 | -6,357 | -394 | -111 |
Pretax Income | 7,521 | 8,023 | 1,058 | 34,729 | 24,310 |
Income Tax Expense | -266 | -28 | -1,115 | 3,328 | 1,852 |
Earnings From Continuing Operations | 7,787 | 8,051 | 2,173 | 31,401 | 22,458 |
Earnings From Discontinued Operations | 25 | 11 | -15 | 6 | -434 |
Net Income to Company | 7,812 | 8,062 | 2,158 | 31,407 | 22,024 |
Minority Interest in Earnings | -41 | -31 | -39 | -35 | -45 |
Net Income | 7,771 | 8,031 | 2,119 | 31,372 | 21,979 |
Net Income to Common | 7,771 | 8,031 | 2,119 | 31,372 | 21,979 |
Net Income Growth | -3.24% | 279.00% | -93.25% | 42.74% | 139.97% |
Shares Outstanding (Basic) | 5,683 | 5,664 | 5,643 | 5,608 | 5,601 |
Shares Outstanding (Diluted) | 5,713 | 5,700 | 5,709 | 5,733 | 5,708 |
Shares Change (YoY) | 0.23% | -0.16% | -0.42% | 0.44% | 1.35% |
EPS (Basic) | 1.37 | 1.42 | 0.38 | 5.59 | 3.92 |
EPS (Diluted) | 1.36 | 1.41 | 0.37 | 5.47 | 3.85 |
EPS Growth | -3.37% | 284.33% | -93.28% | 41.96% | 136.58% |
Free Cash Flow | - | 9,835 | 4,793 | 26,031 | 29,869 |
Free Cash Flow Per Share | - | 1.73 | 0.84 | 4.54 | 5.23 |
Dividend Per Share | 1.720 | 1.680 | 1.640 | 1.600 | 1.560 |
Dividend Growth | 2.38% | 2.44% | 2.50% | 2.56% | 2.63% |
Gross Margin | 75.81% | 74.19% | 70.13% | 66.30% | 62.25% |
Operating Margin | 30.62% | 25.66% | 21.02% | 39.38% | 33.19% |
Profit Margin | 12.42% | 12.62% | 3.56% | 31.01% | 27.04% |
Free Cash Flow Margin | - | 15.46% | 8.05% | 25.73% | 36.74% |
EBITDA | 25,688 | 23,322 | 18,774 | 44,869 | 32,084 |
EBITDA Margin | 41.05% | 36.65% | 31.52% | 44.35% | 39.47% |
D&A For EBITDA | 6,525 | 6,994 | 6,258 | 5,028 | 5,104 |
EBIT | 19,163 | 16,328 | 12,516 | 39,841 | 26,980 |
EBIT Margin | 30.62% | 25.66% | 21.02% | 39.38% | 33.19% |
Effective Tax Rate | - | - | - | 9.58% | 7.62% |
Revenue as Reported | 62,579 | 63,627 | 59,553 | 101,175 | 81,288 |
Advertising Expenses | - | 3,300 | 3,700 | 2,800 | 2,000 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.